Once-weekly semaglutide use in patients with type 2 diabetes: results from the sure Spain multicentre, prospective, observational study

dc.contributor.author	Bellido, Virginia
dc.contributor.author	Abreu Padín, Cristina
dc.contributor.author	Catarig, Andrei M.
dc.contributor.author	Clark, A.
dc.contributor.author	Barreto Pittol, S.
dc.contributor.author	Delgado Álvarez, Elías
dc.date.accessioned	2023-03-15T10:35:15Z
dc.date.available	2023-03-15T10:35:15Z
dc.date.issued	2022
dc.identifier.citation	Journal of Clinical Medicine, 11(17) (2022); doi:10.3390/jcm11174938
dc.identifier.issn	2077-0383
dc.identifier.uri	http://hdl.handle.net/10651/67167
dc.description.sponsorship	This study was funded by Novo Nordisk A/S.
dc.language.iso	eng
dc.relation.ispartof	Journal of Clinical Medicine
dc.rights	© 2022 Los autores
dc.rights	CC Reconocimiento 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137763884&doi=10.3390%2fjcm11174938&partnerID=40&md5=24eedf2f3cbda9de4f532d9b4657f5bc
dc.title	Once-weekly semaglutide use in patients with type 2 diabetes: results from the sure Spain multicentre, prospective, observational study
dc.type	journal article
dc.identifier.doi	10.3390/jcm11174938
dc.relation.publisherversion	http://dx.doi.org/10.3390/jcm11174938
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons